Earnings Feed
Start Free
Alamar Biosciences, Inc.·4

Apr 20, 8:35 PM ET

White Timothy Ogden 4

4 · Alamar Biosciences, Inc. · Filed Apr 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Alamar Biosciences (ALMR) President Timothy Ogden Receives RSUs, Reclassifies Shares

What Happened

  • Timothy Ogden, President of Alamar Biosciences (ALMR), received equity awards and underwent share reclassifications. He was granted 163,358 RSUs (reported as a derivative grant on 2026-04-16) and 37,220 RSUs (granted 2026-04-20) — a total of 200,578 RSUs — each reported at $0.00 (no cash paid). Separately, entries show a reclassification/conversion of 454,583 Class B shares into Common Stock and a series of matching “other acquisition or disposition (J)” entries (various small lots) reported at $0.00, which reflect non‑cash reclassification/conversion activity rather than open‑market trades.

Key Details

  • Transaction dates and prices: grants on 2026-04-16 (163,358 RSUs) and 2026-04-20 (37,220 RSUs); multiple reclassification/conversion entries on 2026-04-20 and 2026-04-16 — all at $0.00 (no cash exchanged).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Notable footnotes from the filing:
    • F1: Each Class B share was reclassified into one share of Common Stock immediately prior to the IPO.
    • F2: RSU grants vest monthly from the grant date, subject to continued service.
    • F3–F9/F4: describe vesting schedules for various option grants (some monthly, some 25% cliff + monthly thereafter; one footnote indicates fully vested).
  • Filing timeliness: Form filed 2026-04-20 covering transactions on 2026-04-16 and 2026-04-20; this filing date appears timely (no late‑filing flag shown).

Context

  • These were awards and reclassifications — not open‑market purchases or cash sales — so they reflect company equity compensation and structural conversion (Class B → Common) rather than a CEO buying or selling stock in the market. RSUs vest over time (see F2), so the reported grants do not immediately represent freely tradable shares unless specified otherwise.

Insider Transaction Report

Form 4
Period: 2026-04-16
Alamar Biosciences, Inc.ALMR
White Timothy Ogden
President
Transactions
  • Other

    Class B Common Stock

    [F1]
    2026-04-20−454,583→ 0 total
  • Other

    Common Stock

    [F1]
    2026-04-20+454,583→ 454,583 total
  • Award

    Common Stock

    [F2]
    2026-04-20+37,220→ 491,803 total
  • Award

    Stock Option (Right to Buy)

    [F3]
    2026-04-16+163,358→ 163,358 total
    Exercise: $17.00Exp: 2036-04-15→ Common Stock (163,358 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F4]
    2026-04-20−29,357→ 0 total
    Exercise: $0.59Exp: 2031-04-20→ Class B Common Stock (29,357 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F4]
    2026-04-20+29,357→ 29,357 total
    Exercise: $0.59Exp: 2031-04-20→ Common Stock (29,357 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F4]
    2026-04-20−8,726→ 0 total
    Exercise: $2.28Exp: 2032-02-15→ Class B Common Stock (8,726 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F4]
    2026-04-20+8,726→ 8,726 total
    Exercise: $2.28Exp: 2032-02-15→ Common Stock (8,726 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F5]
    2026-04-20−10,686→ 0 total
    Exercise: $3.34Exp: 2034-04-16→ Class B Common Stock (10,686 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F5]
    2026-04-20+10,686→ 10,686 total
    Exercise: $3.34Exp: 2034-04-16→ Common Stock (10,686 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F6]
    2026-04-20−206,782→ 0 total
    Exercise: $3.34Exp: 2035-01-15→ Class B Common Stock (206,782 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F6]
    2026-04-20+206,782→ 206,782 total
    Exercise: $3.34Exp: 2035-01-15→ Common Stock (206,782 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F7]
    2026-04-20−8,532→ 0 total
    Exercise: $3.34Exp: 2035-01-15→ Class B Common Stock (8,532 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F7]
    2026-04-20+8,532→ 8,532 total
    Exercise: $3.34Exp: 2035-01-15→ Common Stock (8,532 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F8]
    2026-04-20−5,775→ 0 total
    Exercise: $3.10Exp: 2035-04-08→ Class B Common Stock (5,775 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F8]
    2026-04-20+5,775→ 5,775 total
    Exercise: $3.10Exp: 2035-04-08→ Common Stock (5,775 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F9]
    2026-04-20−16,333→ 0 total
    Exercise: $7.60Exp: 2036-01-14→ Class B Common Stock (16,333 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F9]
    2026-04-20+16,333→ 16,333 total
    Exercise: $7.60Exp: 2036-01-14→ Common Stock (16,333 underlying)
Footnotes (9)
  • [F1]Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
  • [F2]Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
  • [F3]Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
  • [F4]Fully vested.
  • [F5]The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date.
  • [F6]The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
  • [F7]The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.
  • [F8]Twenty-five percent of the shares subject to the option vest on January 1, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
  • [F9]The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
Signature
/s/ Timothy White|2026-04-20

Documents

1 file
  • 4
    form4-04212026_120426.xmlPrimary